Evidence map›Paper›PMID 35804176›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

Diagnostic accuracy of general dermatologists and supportive oncodermatologists for biopsied cutaneous immune-related adverse events.

Leah L Thompson, Jordan T Said, Edward B Li, Jaewon Yoon, Nira A Krasnow, Gabriel E Molina, Nicole J Polyakov, Ruth K Foreman, Nicole R LeBoeuf, Steven T Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. International survey on training of dermatology residents in supportive oncodermatology: the RESCUE study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  3. Access to dermatologic care for cancer patients: employment of an oncodermatology referral system.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Leah L Thompson *Department of Dermatology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, 02114, USA.
Jordan T Said *Department of Dermatology, Brigham and Women's Hospital & Harvard Medical School, 221 Longwood Avenue, Boston, MB, 02215, USA.
Edward B LiDepartment of Dermatology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, 02114, USA.
Jaewon YoonDepartment of Dermatology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, 02114, USA.
Nira A KrasnowDepartment of Dermatology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, 02114, USA.
Gabriel E MolinaDepartment of Dermatology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, 02114, USA.
Nicole J PolyakovDepartment of Dermatology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, 02114, USA.
Ruth K ForemanDepartment of Pathology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, 02114, USA.
Nicole R LeBoeufDepartment of Dermatology, Brigham and Women's Hospital & Harvard Medical School, 221 Longwood Avenue, Boston, MB, 02215, USA. nleboeuf@bwh.harvard.edu.
Steven T ChenDepartment of Dermatology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, 02114, USA.

Funding

Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI SORGER, PETER KARL · 2018 to 2022
$10.8M
NCI NIH HHS U54 CA225088
6 · The paper itself

Abstract

purposeSupportive oncodermatology has been shown to improve several aspects of care for patients with cancer, but research showing improved diagnostic accuracy as a benefit of supportive oncodermatology is largely lacking. We thus aimed to evaluate different dermatologist groups' diagnostic accuracy for heterogenous cutaneous toxicities, using cutaneous immune-related adverse events (cirAEs) from immune checkpoint inhibitors (ICIs) as a test model.

methodsBilling/requisition codes were used to identify patients who initiated programmed death-1/ligand-1 (PD-1/PD-L1) ICIs between 2010 and 2019 at Dana-Farber Cancer Institute/Brigham and Women's Hospital/Massachusetts General Hospital and underwent a subsequent skin biopsy. For each biopsied cirAE, pre-biopsy clinical diagnoses and post-biopsy clinico-pathologic diagnoses were retrospectively obtained from the medical record. Each biopsy-ordering dermatology provider was categorized as a general dermatologist or supportive oncodermatologist on the basis of providing clinical care within a cancer-center or attending on a hospital/clinic service dedicated to anti-cancer drug-related skin toxicities.

resultsOf 4,183 patients who initiated anti-PD-1/PD-L1 therapy between 2010 and 2019, 101 (2.4%) patients collectively had 104 biopsied cirAEs. In more than one-third of all reviewed biopsied cirAEs (n = 39, 37.5%), histopathology results frequently led to revision of the pre-biopsy clinical diagnosis. The rate of initial cirAE misclassification amongst supportive oncodermatologists was significantly lower than that amongst general dermatologists (18/66, 27.3% vs. 21/38, 55.3%; Fischer's-exact-test p = 0.006).

conclusionExperienced supportive oncodermatologists may benefit patient care through increased diagnostic accuracy for skin toxicities from ICIs. Collectively, these results underscore that both skin biopsy from any dermatology provider and oncodermatology referral (where available) are valuable resources that should be integrated into supportive cancer care.

Indexed as

Drug-Related Side Effects and Adverse ReactionsNeoplasmsSkin DiseasesB7-H1 AntigenBiopsyDermatologistsFemaleHumansImmune Checkpoint InhibitorsLigandsRetrospective StudiesB7-H1 AntigenImmune Checkpoint InhibitorsLigandsDiagnostic accuracyImmune checkpoint inhibitorsImmune-related adverse eventsOncodermatologySkin toxicitySupportive oncodermatology

Identifiers

PMID35804176
PMCPMC9993019

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.